title: Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
abstract: BACKGROUND
  The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.
  
  
  METHODS
  Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.
  
  
  RESULTS
  Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.
  
  
  CONCLUSIONS
  P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.
authors.affiliation: Department of Pediatrics, University of Kentucky, Lexington KY 40563-0284, USA. Electronic address: mianst0@uky.edu.
authors.forename: Michael
authors.initials: M
authors.lastname: Anstead
authors.affiliation: Seattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
authors.forename: Sonya L
authors.initials: SL
authors.lastname: Heltshe
authors.affiliation: Seattle Children's Research Institute, Seattle WA 98121, USA.
authors.forename: Umer
authors.initials: U
authors.lastname: Khan
authors.affiliation: Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee WI 53226, USA.
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Barbieri
authors.affiliation: Mediagnost®, Aspenhaustr. 25, 72770 Reutlingen, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Langkamp
authors.affiliation: Universitätsklinikum Tübingen, Institut für Medizinische Mikrobiologie und Hygiene, Wilhelmstr. 31, 72074 Tübingen, Germany.
authors.forename: Gerd
authors.initials: G
authors.lastname: Döring
authors.affiliation: Department of Pediatric Pulmonology, Children's Hospital of Wisconsin, Milwaukee WI, 53226, USA.
authors.forename: Shimoni
authors.initials: S
authors.lastname: Dharia
authors.affiliation: Seattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Gibson
authors.affiliation: Department of Anesthesiology and Pain Medicine, Seattle Children's Hospital, Seattle WA 98104, USA.
authors.forename: Miriam M
authors.initials: MM
authors.lastname: Treggiari
authors.affiliation: Seattle Children's Research Institute, Seattle WA 98121, USA.
authors.forename: James
authors.initials: J
authors.lastname: Lymp
authors.affiliation: Seattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
authors.forename: Margaret
authors.initials: M
authors.lastname: Rosenfeld
authors.affiliation: Seattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
authors.forename: Bonnie
authors.initials: B
authors.lastname: Ramsey
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001431:Bacteriological Techniques; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D011552:Pseudomonas Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D012008:Recurrence; D012307:Risk Factors; D012698:Serologic Tests
chemical_list: D000900:Anti-Bacterial Agents